Abstract
A distributed delay approach was proposed in this paper to model delayed outcomes in pharmacokinetics and pharmacodynamics studies. This approach was shown to be general enough to incorporate a wide array of pharmacokinetic and pharmacodynamic models as special cases including transit compartment models, effect compartment models, typical absorption models (either zero-order or first-order absorption), and a number of atypical (or irregular) absorption models (e.g., parallel first-order, mixed first-order and zero-order, inverse Gaussian, and Weibull absorption models). Real-life examples were given to demonstrate how to implement distributed delays in Phoenix® NLME™ 8.0, and to numerically show the advantages of the distributed delay approach over the traditional methods.
Similar content being viewed by others
References
Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, Legangneux E (1999) Integrated modeling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 47:483–491
Baek IH, Kang W, Yun HY, Lee SS, Kwon KI (2011) Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism. J Clin Pharm Ther 36:390–398
Banks HT, Bortz DM, Holte SE (2003) Incorporation of variability into the modeling of viral delays in HIV infection dynamics. Math Biosci 183:63–91
Banks HT, Hu S, Thompson WC (2014) Modeling and inverse problems in the presence of uncertainty. Chapman and Hall/CRC Press, Boca Raton
Brvar N, Mateovic-Rojnik T, Grabnar I (2014) Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations. Int J Pharm 473:170–178
Chae JW, Baek IH, Lee BY, Cho SK, Kwon KI (2012) Population PK/PD analysis of metformin using the signal transduction model. Br J Clin Pharmacol 74:815–823
Csajka C, Drover D, Verotta D (2005) The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption. Pharm Res 22:1227–1235
Fargue DM (1973) R\(\acute{e}\)ducibilit\(\acute{e}\) des syst\(\grave{e}\)mes h\(\acute{e}\)r\(\acute{e}\)ditaires a des syst\(\grave{e}\)mes dynamiques. C R Acad Sci Paris Ser B 277:471–473
Felmlee MA, Morris ME, Mager DE (2012) Mechanism-based pharmacodynamic modeling. Methods Mol Biol 929:583–600
Gabrielsson J, Weiner D (2016) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 5th edn. Swedish Pharmaceutical Press, Stockholm
Glass L, Beuter A, Larocque D (1988) Time delays, oscillations, and chaos in physiological control systems. Math Biosci 90:111–125
Godfrey KR, Arundel PA, Dong Z, Bryant RT (2011) Modelling the double peak phenomenon in pharmacokinetics. Comput Methods Programs Biomed 104:62–69
Hale JK (1977) Theory of Functional Differential Equations. Springer-Verlag, New York
Hartmann D, Gysel D, Dubach UC, Forgo I (1990) Pharmacokinetic modeling of the plasma concentrationtime profile of the vitamin retinyl palmitate following intramuscular administration. Biopharm Drug Dispos 11:689–700
Holford NH, Ambros RJ, Stoeckel K (1992) Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 20:421–442
Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294–305
Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406–419
Kagan L (2014) Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. Drug Metab Dispos 42:1890–1905
Karmakar MK, Ho AM, Law BK, Wong AS, Shafer SL, Gin T (2005) Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. Anesthesiology 103:704–711
Katsube T, Ishibashi T, Kano T, Wajima T (2016) Population pharmacokinetic and pharmacodynamic modeling of lusutrombopag, a newly developed oral thrombopoietin receptor agonist, in healthy subjects. Clin Pharmacokinet 55:1423–1433
Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286–296
Koch G, Krzyzanski W, Pérez-Ruixo JJ, Schropp J (2014) Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. J Pharmacokinet Pharmacodyn 41:291–318
Krzyzanski W (2010) Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn 38:179–204
Krzyzanski W, Perez-Ruixo JJ, Vermeulen A (2008) Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. J Pharmacokinet Pharmacodyn 35:349–377
Kuang Y (1993) Delay differential equations with applications in population dynamics. Academic Press, New York
Lobo ED, Balthasar JP (2002) Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4:E42
Louizos C, Yáñez JA, Forrest ML, Davies NM (2014) Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. J Pharm Pharm Sci 17:34–91
MacDonald N (1978) Time lags in biological models. Lecture notes in biomathematics. Springer, Berlin
Mallet-Paret J, Nussbaum RD (2011) Stability of periodic solutions of state-dependent delay-differential equations. J Differential Equ 250:4085–4103
Manetsch TJ (1976) Time-varying distributed delays and their use in aggregative models of large systems. IEEE Trans Syst Man Cybern 6:547–553
Pétricoul O, Cosson V, Fuseau E, Marchand M (2007) Population models for drug absorption and enterohepatic recycling. In: Ette E, Williams P (eds) Pharmacometrics: the science of quantitative pharmacology. Wiley, Hoboken, pp 345–382
Ruan S (2006) Delay differential equations in single species dynamics. In: Arino O, Hbid M, Dads E (eds) Delay differential equations and applications. Springer, Dordrecht, pp 477–517
Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711–726
Shen J, Boeckmann A, Vick A (2012) Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J Pharmacokinet Pharmacodyn 39:251–262
Simeoni M, Magni P, Cammia C, Nicolao GD, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094–1101
Smith H (2011) An introduction to delay differential equations with applications to the life science. Springer, New York
Vauquelin G, Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488–508
Verotta D (1996) Concepts, properties, and applications of linear systems to describe the distribution, indentify input, and control endogenous substances and drugs in biological systems. Crit Rev Bioeng 24:73–139
Weiss M (1996) A novel extravascular input function for the assessment of drug absorption in bioavailability studies. Pharm Res 13:1547–1553
Wendling T, Ogungbenro K, Pigeolet E, Dumitras S, Woessner R, Aarons L (2015) Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects. Pharm Res 32:1764–1778
Wright DF, Winter HR, Duffull SB (2011) Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol 71:815–823
Yates JWT (2008) Mathematical properties and parameter estimation for transit compartment pharmacodynamic models. Eur J Pharm Sci 34:104–109
Zhang X, Nieforth K, Lang J, Rouzier-Panis R, Reynes J, Dorr A, Kolis S, Stiles M, Kinchelow T, Patel I (2002) Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 72:10–19
Zhou H (2003) Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43:211–227
Acknowledgements
Part of results in this paper was presented in ACOP 2015. The authors would like to thank Drs. Kairui Feng and Robert Leary for their valuable inputs on this. We also thank Drs. Michael Tomashevskiy and Dmitriy Voronov for their careful review of this manuscript and for providing valuable feedback. In addition, the authors are grateful to the editor and two anonymous referees for their helpful comments and constructive suggestions which led to an improved version of the paper.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: Relationship between the discrete delay and the gamma distributed delay
Let \({\mathcal {T}}\) be a random variable that is gamma distributed with rate parameter \(\kappa\) and shape parameter \(\nu\). Then its mean \(\mu\) and variance \(\sigma ^{2}\) are respectively given by
If \({\mathcal {T}}\) is viewed as a delay time, then \(\mu\) represents the mean delay time, and \(\sigma ^{2}\) gives a measure of the degree of concentration of the delay about its mean.
Equation (56) implies that, for the given mean delay time \(\mu\), \(\sigma ^{2} \rightarrow 0\) as the shape parameter \(\nu \rightarrow +\infty\). Thus, the discrete delay can be recovered as a limit of gamma distributed delays (see Fig. 5 for a visualization of this).
Appendix 2: Using the linear chain trick to reduce (3) to a system of ODEs in the case where g is the PDF of an Erlang distribution
Since the linear chain trick is an elegant method and is rarely known in the PKPD literature, we demonstrate how one can use this approach to reduce (3) to a system of ODEs in the case where g is the PDF of an Erlang distribution given by
Here \(\kappa\) is the rate parameter (a positive number), \(n\) denotes the shape parameter (a positive integer).
By using the transformation \(s = t-\tau\), we see that (3) can be equivalently written as
Hence, to show that (3) can be reduced to a system of ODEs, it is equivalent to show that (58) can be reduced to a system of ODEs. To do that, we let
that is,
for \(j=1,2,\ldots ,n\), and
Equation (59) implies that
Differentiating both sides of the above equation with respect to t yields that
For any \(j\ge 2\), differentiating both sides of (59) with respect to t gives that
By (59), (61) and (62), we see that with an Erlang distributed delay having rate parameter \(\kappa\) and shape parameter \(n\), (58) reduces to the following system of ODEs
with \({\mathcal{S}} = x_{n}\), where \(S_{0}\) denotes the history function (that is, \(S(t) = S_{0}(t)\) for \(t\le 0\)).
Appendix 3: Dynamic behavior of the logistic growth model with a gamma distributed delay
Notice that the logistic growth model with a gamma distributed delay (42) is extended from the following well-known logistic growth model
where r denotes the intrinsic growth rate, K is the carrying capacity, and \(S_{0}\) is a positive constant. As demonstrated in Fig. 6, the solution to (63) has a sigmoidal shape and is asymptotic to the carrying capacity K. To have some idea of the effect of the delay on the dynamics, the solutions to (42) obtained with the same shape parameter value (ShapeParam = 2.5) but different mean delay times are plotted against time t, and are shown in Fig. 6. This figure indicates that introducing a delay in (63) produces an oscillation around the carrying capacity. Specifically, when the mean delay time is two, the oscillation is damped in time with the solution eventually approaching to the carrying capacity. As the mean delay time increases to four, the oscillation is sustained. This example clearly shows that DDEs can exhibit richer dynamics than their corresponding ODEs. In addition, one can adjust the mean delay time to achieve desired type of oscillations.
Appendix 4: PML source code for example 1
Appendix 5: PML source code for example 2
Appendix 6: Using the linear chain trick to reduce time-varying distributed delay (51) to a system of ODEs in the case where g is given by (53)
Here we demonstrate how to use the linear chain trick to reduce (51) to a system of ODEs in the case where g is given by (53). By using the transformation \(s = t-\tau\), we see that (51) can be equivalently written as
Hence, to show that (51) can be reduced to a system of ODEs, it is equivalent to show that (64) can be reduced to a system of ODEs. To do that, we let
that is,
for \(j=1,2,\ldots ,n\), and
Equation (65) implies that
Differentiating both sides of the above equation with respect to t yields that
For any \(j\ge 2\), differentiating both sides of (65) with respect to t gives that
By the above Eqs. (65) and (67), Eq. (64) reduces to the following system of ODEs
with \({\mathcal{S}}(t) = \psi (t) z_{n}(t)\), and \(z_{i}^{0}\) given by
for \(i=1,2,\ldots , n\), where \(S_{0}\) denotes the history function (that is, \(S(t) = S_{0}(t)\) for \(t\le 0\)).
Rights and permissions
About this article
Cite this article
Hu, S., Dunlavey, M., Guzy, S. et al. A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies. J Pharmacokinet Pharmacodyn 45, 285–308 (2018). https://doi.org/10.1007/s10928-018-9570-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-018-9570-4